 |
|
Einstein researchers find potential new drugs for tuberculosis
March 27, 2006Researchers at the Albert Einstein College of Medicine of Yeshiva University have synthesized chemicals that are up to 10 times more effective than isoniazid, the leading anti-tuberculosis drug. The finding could lead to badly needed new drugs for combating tuberculosis bacteria, which each year kill an estimated 2.4 million people worldwide. The study appears in the March issue of Chemistry & Biology.
One of the chemicals, 2-HA, was found to be four times more lethal than isoniazid against the bacteria, while the other, 2-OA, proved 10 times more effective. These chemically similar drugs don't appear to harm higher organisms, so they could probably be used against TB bacteria without risk to patients.
"Drug-resistant mycobacterium tuberculosis is a worldwide problem, particularly in people with weakened immune systems such as those infected with HIV," notes senior author Dr. William Jacobs, a Howard Hughes Medical Institute investigator at Einstein, as well as professor of microbiology & immunology and molecular genetics. "So we urgently need to develop new and more effective antituberculosis drugs."
Isoniazid, today's first-line anti-TB drug, stops TB bacteria from forming mycolic acid, a key building block for their cell walls. It does the job by targeting an enzyme called InhA. Trying to improve upon isoniazid, the Einstein researchers synthesized more than a dozen chemical "decoys" for InhA to latch onto, to prevent the enzyme from catalyzing its normal cell-wall-building reaction. Two of these decoy chemicals, 2-HA and 2-OA, proved much more potent than isoniazid at killing the bacteria-but not in the way the researchers expected.
"We were surprised to find that 2-HA and 2-OA were actually being metabolized in mycobacteria into two different drugs, each of which inhibits a different biochemical pathway," says Dr. Catherine Vilchîze, a study co-author in Dr. Jacobs' laboratory. "The pathways that they block-fatty acid and mycolic acid synthesis and fatty acid degradation-are essential for bacterial survival, and this combined inhibition had a powerful effect against the microbes. To our knowledge, this is the first example of an antibacterial compound that inhibits several pathways to achieve its effect."
The Einstein researchers are now trying to improve on the potency of 2-HA and 2-OA by synthesizing analogues (chemically similar compounds) to them.
"We're hopeful that these new compounds will prove even more toxic to TB bacteria and could help usher in a new era of TB therapy," says Dr. Vilchîze.
Albert Einstein College of Medicine
Isoniazid, today's first-line anti-TB drug, stops TB bacteria from forming mycolic acid, a key building block for their cell walls. It does the job by targeting an enzyme called InhA. Trying to improve upon isoniazid, the Einstein researchers synthesized more than a dozen chemical "decoys" for InhA to latch onto, to prevent the enzyme from catalyzing its normal cell-wall-building reaction. Two of these decoy chemicals, 2-HA and 2-OA, proved much more potent than isoniazid at killing the bacteria-but not in the way the researchers expected.
"We were surprised to find that 2-HA and 2-OA were actually being metabolized in mycobacteria into two different drugs, each of which inhibits a different biochemical pathway," says Dr. Catherine Vilchîze, a study co-author in Dr. Jacobs' laboratory. "The pathways that they block-fatty acid and mycolic acid synthesis and fatty acid degradation-are essential for bacterial survival, and this combined inhibition had a powerful effect against the microbes. To our knowledge, this is the first example of an antibacterial compound that inhibits several pathways to achieve its effect."
The Einstein researchers are now trying to improve on the potency of 2-HA and 2-OA by synthesizing analogues (chemically similar compounds) to them.
"We're hopeful that these new compounds will prove even more toxic to TB bacteria and could help usher in a new era of TB therapy," says Dr. Vilchîze.
Albert Einstein College of Medicine
Tuberculosis Current Events and Tuberculosis News RSSSensitive nanowire disease detectors made by Yale scientists
Yale scientists have created nanowire sensors coupled with simple microprocessor electronics that are both sensitive and specific enough to be used for point-of-care (POC) disease detection, according to a report in Nano Letters.
Scientists identify gene that may make humans more vulnerable to pulmonary tuberculosis
Researchers from the Genome Institute of Singapore (GIS) and its collaborators have now identified for the first time a new gene that may confer susceptibility to pulmonary tuberculosis.
Gene with probable role in human susceptibility to pulmonary tuberculosis identified
A new gene that may confer susceptibility to pulmonary tuberculosis has been identified by Genome Institute of Singapore (GIS) researchers and their collaborators in The Netherlands, Indonesia, United Kingdom, and the Russian Federation.
Groundbreaking, lifesaving TB vaccine a step closer
Researchers at Aberystwyth University, following a number of years of investment by the Biotechnology and Biological Sciences Research Council (BBSRC), have licensed ground-breaking research to a non-profit product development partnership working to develop new, more effective vaccines against Tuberculosis (TB). This development will give hope that significantly better prevention and treatment of TB will be available within the next few years.
'Deadly dozen' reports diseases worsened by climate change
Health experts from the Wildlife Conservation Society today released a report that lists 12 pathogens that could spread into new regions as a result of climate change, with potential impacts to both human and wildlife health and global economies.
Disease diagnosis in just 15 minutes
Testing for diseases such as cancer and multiple sclerosis could soon be as simple as using a pregnancy testing kit.
New way to make malaria medicine also first step in finding new antibiotics
University of Illinois microbiology professor William Metcalf and his collaborators have developed a way to mass-produce an antimalarial compound, potentially making the treatment of malaria less expensive.
How to differentiate abdominal tuberculosis from lymphomas?
The incidence of tuberculosis is increasing. Lymphadenopathy is the most common manifestation of abdominal tuberculosis and may, in up to 55% of cases without other evidence of abdominal involvement, be easily confused with lymphomas involving abdominal lymph nodes.
New insights could lead to a better pneumococcal vaccine
Discovery of a new, previously unknown mechanism of immunity suggests that there may be a better way to protect vulnerable children and adults against Streptococcus pneumoniae (pneumococcal) infection, say researchers at Children's Hospital Boston and Harvard School of Public Health (HSPH).
Tuberculosis drug shows promise against latent bacteria
A new study has shown that an investigational drug (R207910, currently in clinical trials against multi-drug resistant tuberculosis strains) is quite effective at killing latent bacteria. This revelation suggests that R207910 may lead to improved and shortened treatments for this globally prevalent disease.
More Tuberculosis Current Events and Tuberculosis News Articles
| White Death: A History of Tuberculosis by Thomas Dormandy The victims of tuberculosis (TB; usually known as consumption) included not only Keats, the Brontes, Chopin & Chekhov but members of almost every family. It was a killer on a huge scale. This highly praised book provides a history of tuberculosis as a whole. Thomas Dormandy's account of the search for a cure is complemented by a description of the disease's complex natural history; & by portraits... | |
 | Reichman and Hershfield's Tuberculosis: A Comprehensive, International Approach, Third Edition (Two-Volume (Lung Biology in Health and Disease) Thoroughly examining tuberculosis from historical, theoretical, and clinical perspectives, this Third Edition merges state-of-the-art research developments with principles of programmatic TB management. Each of the 50 chapters analyze current studies on TB mechanisms and treatment and will meet the needs of all who work in the field of TB control, whether in low-income, high-prevalence areas or... |
 | The White Plague: Tuberculosis, Man, and Society by Rene J. Dubos |
 | The Forgotten Plague: How the Battle Against Tuberculosis Was Won - And Lost by Frank Ryan Tuberculosis has claimed more than a billion lives worldwide. In this acclaimed book, Dr. Frank Ryan tells the remarkable story of the dedicated doctors, chemists, and bacteriologists who halted the course of this ferocious disease--until the "old enemy" found in AIDS a deadly ally to form a drug-resistant synergy. 8 pages of... |
 | Captain of Death: The Story of Tuberculosis by Thomas M. Daniel The dramatic story of tuberculosis is told here in a straightforward and accessible style. It presents the stories of persons connected with the disease, either as victims, or as those who made contributions to our knowledge of it; in addition to these personal accounts, the book unfolds the history and explains the pathogenesis of TB. The re-emergence of tuberculosis as a major American public... |
 | The Bioarchaeology of Tuberculosis: A Global View on a Reemerging Disease by CHARLOTTE ROBERTS, JANE BUIKSTRA Though apparently in decline during the first half of the 20th century, tuberculosis has reawakened in both developed and developing countries, particularly among susceptible populations with immunodeficiency disorders.... |
 | Tuberculosis and the Politics of Exclusion: A History of Public Health and Migration to Los Angeles (Critical Issues in Health and Medicine) by Emily K. Abel Though notorious for its polluted air today, the city of Los Angeles once touted itself as a health resort. After the arrival of the transcontinental railroad in 1876, publicists launched a campaign to portray the city as the promised land, circulating countless stories of miraculous cures for the sick and debilitated. As more and more migrants poured in, however, a gap emerged between... |
 | Living in the Shadow of Death: Tuberculosis and the Social Experience of Illness in American History by Sheila M. Rothman Tuberculosis -- once the cause of as many as one in five deaths in the U.S. -- crossed all boundaries of class and gender, but the methods of treatment for men and women differed radically. While men were encouraged to go out to sea or to the open country, women were expected to stay at home, surrounded by family, to anticipate a lingering death. Several women, however, chose rather to head for... |
 | Tuberculosis: Arresting Everyone's Enemy |
 | Handbook of Tuberculosis Tuberculosis (TB), a deadly airborne disease caused by the bacterium Mycobacterium tuberculosis, takes the lives of almost 2 million people each year and is considered to be the most common infectious disease in the world. However, thanks to the efforts of researchers such as the volumes’ lead editor, Dr. Stefan H. E. Kaufmann, there have been several recent advances in fighting the disease. ... |
| © 2008 BrightSurf.com |